Clinquest Partners with Excelimmune

Biopharmaceutical firm Excelimmune Inc. has acquired $1 million in a Series B investment round to support studies of Staphguard, the company’s drug candidate to treat methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a potentially fatal bacterial infection that is acquired in healthcare settings. It is estimated to infect as many as one million patients annually.

In order to advance towards an IND filing, Excelimmune is partnering with Clinquest. “We are very excited to help advance this novel and important new therapeutic candidate to address a large unmet medical need,” said Dr. Cornelis Wortel, CMO of Clinquest.

 

For more information:

Mass High Tech - "Excelimmune takes in $1M in Series B round"

Excelimmune - "Excelimmune Receives $1 Million in Series-B Funding"